Abstract
Background: It was found that breast cancer susceptibility protein 1 (BRCA 1) binds to estrogen receptor alpha (ERα) and inhibits its activity by direct interaction between domains within the amino terminus of BRCA 1 and the carboxy terminus of ER alpha.
Objectives: The present work focuses to identify a new class of BRCA 1 mimetics that work differently from conventional anti-estrogens.
Methods: A novel class of hybrids having coumate and benzimidazolone scaffolds were designed to mimic BRCA 1 protein, suppressing the tumor activity of breast cancer cells. In silico molecular docking studies of the designed ligands were performed on BRCA 1 binding cavity of ER alpha.
Results: The designed hybrids which gave significant docking scores and had optimum binding interactions with key residues were selected for synthesis and in vitro assay.
Conclusion: The compounds NY1 and NY2 exhibited significant effects on suppressing MDAMB- 231 cells in the concentration of 24 μg/ml and 44 μg/ml, respectively.
Keywords: Breast cancer, scaffold, BRCA1, coumate, benzimidazolone, ERα.
Current Computer-Aided Drug Design
Title:A New Class of Coumate Benzimidazole Hybrids as BRCA 1 Mimetics Through Unconventional Binding Mode; Synthesis and Preliminary Cytotoxicity Screening
Volume: 16 Issue: 6
Author(s): Selvaraj Jubie*, Shyam Sundar, Neetu Yadav, Podila Naresh, Ashish Wadhwani and Jawahar Natarajan
Affiliation:
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Udhagamandalam JSS Academy of Higher Education & Research, Mysore,India
Keywords: Breast cancer, scaffold, BRCA1, coumate, benzimidazolone, ERα.
Abstract:
Background: It was found that breast cancer susceptibility protein 1 (BRCA 1) binds to estrogen receptor alpha (ERα) and inhibits its activity by direct interaction between domains within the amino terminus of BRCA 1 and the carboxy terminus of ER alpha.
Objectives: The present work focuses to identify a new class of BRCA 1 mimetics that work differently from conventional anti-estrogens.
Methods: A novel class of hybrids having coumate and benzimidazolone scaffolds were designed to mimic BRCA 1 protein, suppressing the tumor activity of breast cancer cells. In silico molecular docking studies of the designed ligands were performed on BRCA 1 binding cavity of ER alpha.
Results: The designed hybrids which gave significant docking scores and had optimum binding interactions with key residues were selected for synthesis and in vitro assay.
Conclusion: The compounds NY1 and NY2 exhibited significant effects on suppressing MDAMB- 231 cells in the concentration of 24 μg/ml and 44 μg/ml, respectively.
Export Options
About this article
Cite this article as:
Jubie Selvaraj *, Sundar Shyam , Yadav Neetu , Naresh Podila , Wadhwani Ashish and Natarajan Jawahar , A New Class of Coumate Benzimidazole Hybrids as BRCA 1 Mimetics Through Unconventional Binding Mode; Synthesis and Preliminary Cytotoxicity Screening, Current Computer-Aided Drug Design 2020; 16 (6) . https://dx.doi.org/10.2174/1573409916666191231102046
DOI https://dx.doi.org/10.2174/1573409916666191231102046 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Decoy Oligodeoxynucleotides-Based Approach to Renal Diseases
Current Drug Targets Identifying Breast Cancer-induced Gene Perturbations and its Application in Guiding Drug Repurposing
Current Bioinformatics Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy HumDLoc: Human Protein Subcellular Localization Prediction Using Deep Neural Network
Current Genomics Melatonin, its Metabolites and its Synthetic Analogs as Multi-Faceted Compounds: Antioxidant, Prooxidant and Inhibitor of Bioactivation Reactions
Current Medicinal Chemistry Editorial (Thematic Issue: The Effects of Anticancer Agents on Cell Apoptosis and on the Expression of Cancer - Related Genes)
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Potential of miR-7 in Cancers
Mini-Reviews in Medicinal Chemistry Cerenkov Luminescence Imaging at a Glance
Current Molecular Imaging (Discontinued) International Conference on Personalized Medicine: “Genes and Medicine” 19-20 September 2009, Hong Kong Science Park, Hong Kong SAR
Current Pharmacogenomics and Personalized Medicine PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Molecular Actions of Polyhalogenated Arylhydrocarbons (PAHs) in Female Reproduction
Current Medicinal Chemistry Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design Biomarkers and Osteosarcoma and IGF
Recent Patents on Biomarkers Meet Our Editorial Board Member:
Recent Patents on Anti-Cancer Drug Discovery Novel Drugs Targeting Microtubules: the Role of Epothilones
Current Pharmaceutical Design Proteomic Analysis of Mitochondrial Proteins on the Mechanism of Apoptotic Under Amorphophallus konjac Tuber (KONJAC) Extracts in Gas tric Cancer Cell
Current Proteomics Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology Cholesterol-Rich Nanoemulsions (LDE) for Drug Targeting of Cholesteryl-Succinyl- 5-Fluorouracil Conjugate
Current Nanoscience